Collectively, the above clinical data suggest that tobacco smoking, tumor-infiltrating T lymphocytes, and the tumor mutation burden may play critical roles in IL-17A-IL-17RA/IL-17RC-modulated LUAD progression. This evidence concerns the gene IL17A and neoplasm.